30 August 2016
: Case report
DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy
Daisuke MiyazuABDEF, Nobuhiro KodamaABD, Daiki YamashitaB, Hirokazu TanakaB, Sachiko InoueB, Osamu ImakyureBD, Masaaki HirakawaAD, Hideki ShutoABDEF, Yasufumi KataokaAEGDOI: 10.12659/AJCR.899149
Am J Case Rep 2016; 17:625-631
Abstract
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening syndrome comprising severe skin eruption, fever, eosinophilia, lymphadenopathy, and involvement of internal organs. Here, we describe a case of DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration.
CASE REPORT: A 79-year-old male was admitted to our hospital for the treatment of injuries incurred in a traffic accident. Eosinophilia and lung dysfunction appeared after vancomycin administration. These symptoms were improved temporarily by withdrawal of vancomycin and administration of corticosteroid, but exacerbated by subsequent teicoplanin administration. These symptoms disappeared after discontinuation of teicoplanin. Based on comprehensive assessment of the overall clinical course, we judged that DRESS syndrome was induced by cross-reactivity between vancomycin and subsequent teicoplanin administration. Using the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system, we categorized DRESS syndrome related to vancomycin and teicoplanin as “probable.” We describe, for the first time, DRESS syndrome (defined using the RegiSCAR scoring system) caused by cross-reactivity between vancomycin and subsequent teicoplanin administration.
CONCLUSIONS: Clinicians should be aware that DRESS syndrome can be induced by cross-reactivity between vancomycin and teicoplanin.
Keywords: Drug Hypersensitivity Syndrome, Lung Diseases, Interstitial, Teicoplanin, Vancomycin
SARS-CoV-2/COVID-19
29 March 2023 : Editorial
Med Sci Monit In Press; DOI: 10.12659/MSM.940519
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
In Press
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939200
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939365
28 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939387
27 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939170
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347